M&A Deal Summary

Kelso Pharma Acquires Stirling Anglian

On January 14, 2022, Kelso Pharma acquired life science company Stirling Anglian

Acquisition Highlights
  • This is Kelso Pharma’s 1st transaction in the Life Science sector.
  • This is Kelso Pharma’s 1st transaction in the United Kingdom.

M&A Deal Summary

Date 2022-01-14
Target Stirling Anglian
Sector Life Science
Buyer(s) Kelso Pharma
Deal Type Add-on Acquisition

Target

Stirling Anglian

Glasgow, United Kingdom
website
Stirling Anglian is committed to medicines optimisation. It has sourced and developed a portfolio of medicines to help the NHS curb waste, across a range of conditions that currently place unnecessary and avoidable pressure on NHS resources. At a time when there is such pressure on the NHS to reduce costs, the company believes that it provides a real and practical solution. It works closely with stakeholders across the NHS to identify real-world problems and develop value-based solutions that support the delivery of efficient and cost-effective healthcare.

Search 191,421 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Kelso Pharma

Kelso, United Kingdom

website


Category Company
Founded 2022
Sector Life Science
DESCRIPTION

Kelso Pharma is a business committed to bringing innovative specialty medicines to the European healthcare markets, to provide meaningful benefits to patients and create added value for healthcare stakeholders.


DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (United Kingdom) 1 of 1
Year (2022) 1 of 1